Orthovanadate decreases leptin secretion from isolated mouse fat pads

Area of Science:

• Adipose tissue biology
• Endocrinology
• Molecular signaling

Background:

• Leptin, a key hormone in energy balance, is secreted by adipocytes.
• The regulation of leptin secretion involves complex intracellular signaling pathways.
• Orthovanadate (vanadate) is a phosphatase inhibitor with known cellular effects.

Purpose of the Study:

• To investigate the effect of vanadate on leptin secretion from isolated mouse fat pads.
• To elucidate the signaling mechanisms underlying vanadate-induced changes in leptin secretion.
• To determine the role of adrenergic receptors and protein kinases in this process.

Main Methods:

• Incubation of isolated mouse fat pads with vanadate or insulin.
• Measurement of leptin secretion into the medium.
• Assessment of cellular cyclic AMP (cAMP) levels.
• Use of adrenergic receptor antagonists (propranolol, bupranorol, beta1/beta2 antagonists) and kinase inhibitors (H-89, PKC, Ca/calmodulin kinase inhibitors).
• Measurement of protein synthesis via [3H]-leucine incorporation.

Main Results:

• Vanadate significantly decreased leptin secretion, while insulin increased it.
• Nonspecific beta-adrenergic antagonist (propranolol), specific beta3-adrenergic antagonist (bupranorol), and PKA inhibitor (H-89) partially blocked vanadate's effect.
• Vanadate caused a transient increase in cellular cAMP, inhibited by propranolol and bupranolol.
• Vanadate did not affect protein synthesis, suggesting its effect on leptin is independent of this pathway.

Conclusions:

• Vanadate decreases leptin secretion through a mechanism involving increased cellular cAMP.
• This effect is mediated via beta3-adrenergic receptors and likely involves the activation of cAMP-dependent protein kinase (PKA).
• The regulation of leptin secretion by vanadate is independent of protein synthesis modulation.